NEURONETICS INC (STIM) Stock Price & Overview

NASDAQ:STIMUS64131A1051

Current stock price

1.49 USD
-0.11 (-6.88%)
Last:

The current stock price of STIM is 1.49 USD. Today STIM is down by -6.88%. In the past month the price increased by 29.03%. In the past year, price decreased by -57.56%.

STIM Key Statistics

52-Week Range0.8 - 4.8495
Current STIM stock price positioned within its 52-week range.
1-Month Range0.8 - 1.65
Current STIM stock price positioned within its 1-month range.
Market Cap
102.05M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.59
Dividend Yield
N/A

STIM Stock Performance

Today
-6.88%
1 Week
+17.65%
1 Month
+29.03%
3 Months
+12.68%
Longer-term
6 Months -40.96%
1 Year -57.56%
2 Years -66.39%
3 Years -45.02%
5 Years -87.07%
10 Years N/A

STIM Stock Chart

NEURONETICS INC / STIM Daily stock chart

STIM Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to STIM. When comparing the yearly performance of all stocks, STIM is a bad performer in the overall market: 85.59% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

STIM Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to STIM. STIM has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

STIM Earnings

On March 17, 2026 STIM reported an EPS of -0.1 and a revenue of 41.78M. The company beat EPS expectations (8.09% surprise) and beat revenue expectations (0.72% surprise).

Next Earnings DateMay 4, 2026
Last Earnings DateMar 17, 2026
PeriodQ4 / 2025
EPS Reported-$0.10
Revenue Reported41.777M
EPS Surprise 8.09%
Revenue Surprise 0.72%

STIM Forecast & Estimates

9 analysts have analysed STIM and the average price target is 6.63 USD. This implies a price increase of 344.97% is expected in the next year compared to the current price of 1.49.

For the next year, analysts expect an EPS growth of 20.47% and a revenue growth 10.13% for STIM


Analysts
Analysts82.22
Price Target6.63 (344.97%)
EPS Next Y20.47%
Revenue Next Year10.13%

STIM Groups

Sector & Classification

STIM Financial Highlights

Over the last trailing twelve months STIM reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS increased by 56.93% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-44.50M
Industry RankSector Rank
PM (TTM) N/A
ROA -30.59%
ROE -162.68%
Debt/Equity 2.4
Chartmill High Growth Momentum
EPS Q2Q%69.7%
Sales Q2Q%85.73%
EPS 1Y (TTM)56.93%
Revenue 1Y (TTM)N/A

STIM Ownership

Ownership
Inst Owners34.72%
Shares68.49M
Float33.96M
Ins Owners17.3%
Short Float %28.32%
Short Ratio5.38

STIM Latest News, Press Relases and Analysis

About STIM

Company Profile

STIM logo image Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.

Company Info

IPO: 2018-06-28

NEURONETICS INC

3222 Phoenixville Pike

Malvern PENNSYLVANIA 19355 US

CEO: Keith J. Sullivan

Employees: 716

STIM Company Website

STIM Investor Relations

Phone: 18776007555

NEURONETICS INC / STIM FAQ

What does NEURONETICS INC do?

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.


What is the stock price of NEURONETICS INC today?

The current stock price of STIM is 1.49 USD. The price decreased by -6.88% in the last trading session.


What is the dividend status of NEURONETICS INC?

STIM does not pay a dividend.


What is the ChartMill technical and fundamental rating of STIM stock?

STIM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is NEURONETICS INC worth?

NEURONETICS INC (STIM) has a market capitalization of 102.05M USD. This makes STIM a Micro Cap stock.


What is the outstanding short interest for NEURONETICS INC?

The outstanding short interest for NEURONETICS INC (STIM) is 28.32% of its float.